Six U.S. Market AI Healthcare Stocks Segments Investors Should Watch in 2026

PDF Version

Healthcare artificial intelligence is moving beyond demonstrations and pilot projects. For investors, the opportunity is becoming less about finding one “AI healthcare stock” and more about understanding where the technology can create measurable revenue, improve margins or increase the utilization of existing healthcare infrastructure.

The U.S. Food and Drug Administration maintains a list of AI-enabled medical devices authorized for marketing in the United States, while noting that the list is not comprehensive and is updated periodically. On August 18, 2026, the FDA also issued a discussion paper addressing the regulation of generative-AI-enabled medical devices, including risk assessment, premarket evaluation and postmarket monitoring. Taken together, these developments suggest that healthcare AI is moving toward broader commercialization, although regulatory approval and clinical validation remain essential parts of the investment case.

Early Screening and Precision Diagnosis

Early screening and precision diagnosis may be among the most direct ways to connect AI with healthcare revenue. Unlike a general-purpose software tool, a diagnostic company can monetize its technology through laboratory testing, clinical services, pharmaceutical partnerships and recurring patient monitoring.

The U.S.-listed universe in this category includes Abbott Laboratories, Natera, Guardant Health, Tempus AI, GRAIL, GeneDx and Sophia Genetics. Their business models differ considerably, but each operates somewhere within the broader ecosystem of genetic testing, molecular diagnostics, clinical data or precision medicine.

Natera reported second-quarter 2026 revenue of $752.8 million and processed more than 1 million tests during the quarter. Its oncology testing volume increased sharply year over year, reflecting growing demand for molecular residual disease testing and other precision-medicine applications. Guardant Health also reported strong momentum in screening, with second-quarter screening revenue of $52.9 million and approximately 66,000 Shield screening tests.

Tempus AI offers another version of the model by combining laboratory testing, clinical data and artificial intelligence. The company reported second-quarter 2026 revenue of $382.5 million, while its Data and Applications business grew 28% year over year. Tempus also announced that it had delivered an oncology foundation model to AstraZeneca and agreed to acquire Personalis to expand its molecular residual disease capabilities.

GRAIL illustrates both the potential and the risk of this segment. The company reported that second-quarter Galleri revenue increased 24% year over year to $42.6 million, while test volume surpassed 61,000. However, GRAIL also reported a quarterly net loss of $110.2 million and said it anticipated an FDA advisory committee review of its multi-cancer early-detection test in the fall. Commercial growth does not eliminate regulatory, reimbursement or cash-burn risks.

Investors evaluating this group should look beyond the AI branding. Test volume, reimbursement, clinical utility, repeat usage, laboratory capacity and free cash flow may be more important than the sophistication of the underlying algorithm.

AI Drug Discovery and Computational Biology

AI drug discovery offers some of the sector’s largest theoretical opportunities, but it also carries significant scientific and financial risk. A successful platform could shorten the time required to identify drug candidates, improve patient selection and create valuable partnerships with large pharmaceutical companies. At the same time, a promising model does not guarantee clinical success.

The broader group includes Moderna, BioNTech, CRISPR Therapeutics, AbCellera, Beam Therapeutics, Recursion Pharmaceuticals, Absci, Schrödinger, Certara and Ginkgo Bioworks. However, investors should not treat every biotechnology company that uses computational tools as a pure AI investment. In many cases, the primary investment thesis remains drug development, gene editing, vaccines or laboratory automation.

Recursion is one of the clearest examples of an AI-native drug-discovery company. The company describes its Recursion OS as an AI-enabled, end-to-end platform that integrates biology, chemistry and clinical development. In August 2026, Recursion said Genentech had advanced the first neuroscience target from their collaboration into a joint early-discovery program, offering an example of how platform value may eventually be converted into partnerships and milestone opportunities.

Schrödinger represents a hybrid model that combines software licensing with proprietary and partnered drug-discovery programs. The company has also highlighted Bunsen, its agentic AI co-scientist, as part of its effort to expand the role of computational tools in research organizations.

For investors, the most important questions are whether the platform can generate reproducible scientific results, whether pharmaceutical partners continue to commit capital, how much revenue is recurring, how long the cash runway lasts and whether future financing could dilute shareholders. In this segment, partnership announcements can attract attention, but clinical data and eventual product approvals determine long-term value.

Multi-Omics, Sequencing and Clinical Data Platforms

Artificial intelligence is only as useful as the data available to train and operate it. That makes sequencing companies, clinical-data providers and life-science software platforms potential beneficiaries of the healthcare AI trend.

Examples include IQVIA, Veeva Systems, Illumina, Twist Bioscience and 10x Genomics. These companies occupy different positions within the data ecosystem. IQVIA and Veeva are more closely tied to healthcare intelligence, software and life-science workflows, while Illumina, Twist and 10x Genomics are more exposed to sequencing, laboratory instruments, consumables and research spending.

IQVIA reported second-quarter 2026 revenue of $4.368 billion and said increased adoption of its AI solutions contributed to growth in its Commercial Solutions business. Veeva reported first-quarter fiscal 2027 revenue of $882.9 million, up 16% year over year, while management described Veeva AI as a foundation for the company’s next stage of industry-specific software.

Illumina reported second-quarter 2026 revenue of approximately $1.16 billion and emphasized continued demand for sequencing-intensive applications and expanded multi-omics capabilities. Meanwhile, 10x Genomics acquired Proteintech Genomics to strengthen its multi-omics strategy and announced collaborations focused on diagnostic applications of single-cell and spatial technologies.

This group may appeal to investors who prefer “picks and shovels” exposure rather than the uncertainty of early-stage drug developers. Still, the risks vary. Software and data companies may offer more recurring revenue, while instrument and consumables companies can be affected by laboratory budgets, capital spending cycles and research funding.

Surgical Robotics, Medical Devices and Patient Monitoring

Robotics and connected medical devices provide another route for AI adoption. These companies already have installed hardware, clinical workflows, proprietary data and recurring revenue from instruments, sensors, accessories or software subscriptions.

The broader group includes Intuitive Surgical, Stryker, Medtronic, DexCom, ResMed, Zimmer Biomet, Globus Medical, iRhythm Technologies and PROCEPT BioRobotics. Their direct exposure to AI ranges from robotic assistance and computer vision to remote monitoring, predictive analytics and digital workflow tools.

Intuitive Surgical is one of the strongest examples of a medical-device company with a growing digital and data opportunity. In the second quarter of 2026, worldwide procedures involving its da Vinci and Ion systems grew approximately 16% year over year, revenue increased 19% to $2.89 billion and the da Vinci installed base reached 11,710 systems. The company has also described an AI development strategy built around real-world data from more than 20 million da Vinci procedures.

The investment appeal of this category is that AI does not necessarily need to create an entirely new product. It may increase the productivity of existing devices, improve clinical decision-making or encourage hospitals to use more procedures and monitoring services.

Investors should watch installed-base growth, procedure volume, recurring consumables revenue, reimbursement, regulatory clearances and hospital capital budgets. A technically impressive device can still struggle if hospitals lack the budget or staff required to deploy it.

Digital Care and Healthcare Service Platforms

Digital health platforms are using AI to support clinical documentation, patient engagement, care navigation, triage, prescription workflows and chronic-condition management. Potential U.S.-listed names include Cardinal Health, Molina Healthcare, Hinge Health, Hims & Hers, Doximity, Omada Health, Teladoc and Weave Communications.

Doximity provides an example of AI being integrated into an existing professional network. The company reported fiscal 2026 revenue of $644.9 million and said nearly half of its providers had used its clinical AI during the latest quarter. Its opportunity is not simply to sell an AI chatbot, but to integrate AI into tools physicians already use.

Omada Health combines human-led care teams, connected devices and AI-enabled technology in programs addressing chronic conditions. In the second quarter of 2026, Omada reported revenue of $88 million, up 43% year over year, while total members increased 45%.

Hims & Hers reported second-quarter revenue of $753.2 million, up 38% year over year, and described its strategy as including a doctor-led AI clinical engine. However, the company also reported a net loss of $86.3 million and negative free cash flow of $68.2 million. Teladoc, meanwhile, reported second-quarter revenue of $606.9 million, down 4% year over year. These contrasting results demonstrate that digital-health adoption does not automatically translate into profitability or sustained growth.

In this segment, investors should evaluate customer acquisition costs, retention, gross margins, regulatory compliance, employer and health-plan contracts, prescription practices and cash generation. The companies with the strongest AI narratives may not always be the companies with the strongest financial results.

AI Medical Imaging and Assisted Diagnosis

Medical imaging is one of the most visible areas of healthcare AI because radiology, ultrasound and other imaging workflows generate large quantities of structured data. AI can assist with image acquisition, disease detection, prioritization, treatment planning and workflow management.

GE HealthCare, RadNet and Butterfly Network are among the U.S.-listed companies with exposure to this theme. GE HealthCare reported second-quarter 2026 revenue of $5.3 billion, a backlog of $23.9 billion and FDA 510(k) clearance for an AI-enabled radiation-therapy-planning product. RadNet reported that revenue from its Digital Health segment increased 56.5% year over year to $32.4 million, while annual recurring revenue reached $105.5 million.

Butterfly Network reported second-quarter revenue of $32.6 million, up 39% year over year, and described its business as combining semiconductor-based ultrasound hardware, cloud software and AI. Its approach illustrates how lower-cost imaging devices may expand access while creating opportunities for software and data monetization.

The key question is whether AI improves measurable outcomes. Investors should look for evidence of higher imaging volumes, faster turnaround times, improved radiologist productivity, stronger enterprise contracts or better utilization of existing equipment. FDA clearance is important, but authorization alone does not guarantee commercial adoption.

How Investors Should Evaluate the Theme

A useful framework is to classify healthcare companies as AI-native, AI-enabled or AI-adjacent. AI-native companies depend heavily on platform performance, scientific validation and future partnerships. AI-enabled companies already have products, customers or clinical workflows and are using AI to improve growth, margins or engagement. AI-adjacent companies may provide the data, instruments, distribution or infrastructure required for others to build AI products.

Before investing, shareholders should determine whether AI-related revenue is disclosed separately, whether customer usage is increasing and whether the technology is producing measurable economic benefits. It is also important to review the company’s latest annual and quarterly filings for information about reimbursement, regulatory approvals, data privacy, cybersecurity, litigation, cash burn and potential dilution.

The FDA has emphasized that AI-enabled medical devices require attention to lifecycle management, transparency, bias, safety and effectiveness. These issues can affect product approvals, liability exposure and long-term customer trust.

Final Thoughts

Healthcare AI is not a single investment theme. It is a stack that includes diagnostic testing, drug discovery, sequencing, clinical data, surgical robotics, medical devices, digital care and imaging.

The most durable opportunities may belong to companies that combine proprietary data with regulatory experience, established distribution, recurring revenue and disciplined capital management. Smaller AI-native companies may offer greater upside, but they often carry higher clinical, financing and valuation risk.

As of August 2026, the healthcare AI market is expanding, but the sector remains highly selective. Investors should focus less on attractive presentations and more on clinical evidence, customer adoption, reimbursement and cash flow.

©2026 Ryan Financial Daily